Related references
Note: Only part of the references are listed.PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey
Xavier Paoletti et al.
EUROPEAN JOURNAL OF CANCER (2014)
Adverse Event Reporting in Cancer Clinical Trial Publications
Shanthi Sivendran et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
F. E. Vera-Badillo et al.
ANNALS OF ONCOLOGY (2013)
Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
Julien Peron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J. Voskens et al.
PLOS ONE (2013)
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)
Lynne I. Wagner et al.
SUPPORTIVE CARE IN CANCER (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vemurafenib Sensitivity Skin Reaction after Ipilimumab
James J. Harding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
Bostjan Seruga et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Emerging Toxicity Profiles of Anti-CTLA-4 Antibodies Across Clinical Indications
Anna Maria Di Giacomo et al.
SEMINARS IN ONCOLOGY (2010)
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
Isabelle Pitrou et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Better reporting of harms in randomized trials: An extension of the CONSORT statement
JPA Ioannidis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Completeness of safety reporting in randomized trials - An evaluation of 7 medical areas
JPA Ioannidis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
